Proxygen Appoints Chiara Conti as Chief Scientific Officer
- Proxygen, a biotechnology company based in Vienna, Austria, announced the appointment of Chiara Conti, Ph.D., as its Chief Scientific Officer on March 31, 2026.
- The appointment comes as Proxygen seeks to expand its induced proximity platform and advance assets based on molecular glue degraders.
- Conti joins Proxygen from Blueprint Medicines, where she served as senior director.
Proxygen, a biotechnology company based in Vienna, Austria, announced the appointment of Chiara Conti, Ph.D., as its Chief Scientific Officer on March 31, 2026. Dr. Conti will lead the company’s transition from a discovery-focused organization to clinical-stage execution, focusing on the advancement of its pipeline into clinical development.
The appointment comes as Proxygen seeks to expand its induced proximity platform and advance assets based on molecular glue degraders. This field of drug discovery aims to control protein function by bringing molecules into close proximity to trigger specific biological effects.
Experience in Targeted Protein Degradation
Dr. Conti joins Proxygen from Blueprint Medicines, where she served as senior director. During her seven-year tenure at Blueprint Medicines, she established the company’s targeted protein degradation platform and its early-stage portfolio.
While at Blueprint Medicines, Dr. Conti identified four development candidates. Two of these candidates were advanced to the investigational new drug (IND) stage, and she provided support for two additional clinical programs that reached Phase I.
Expanding the Induced Proximity Platform
Proxygen is pioneering the discovery of next-generation proximity-based therapeutics and molecular glue degraders. The company’s current strategy involves extending its capabilities beyond protein degradation to include a wider range of effectors within the broader induced proximity field.
Bernd Boidol, Ph.D., the Chief Executive Officer of Proxygen, stated that the appointment occurs at a pivotal moment
for the company. He noted that Dr. Conti’s experience in translating discovery into IND-stage programs will be essential for accelerating the company’s transition into clinical trials.
We are moving induced proximity from a discovery paradigm to a scalable, design-driven therapeutic modality.
Bernd Boidol, Ph.D., Chief Executive Officer of Proxygen
Dr. Conti has indicated that Proxygen’s platform is distinguished by its scientific foundation in proximity-driven protein degradation and its capacity to systematically use that knowledge to identify new therapeutics.